17α-alkylated anabolic-androgenic steroid
Stanozolol
Androgen- used historically as an anabolic agent; hepatic and lipid class effects are prominent.
Primary Mechanism of Action
Clinical / Scientific
Stanozolol activates androgen receptors and modifies anabolic and androgenic gene programs. 17α-alkylation permits oral bioavailability at the cost of greater hepatic strain compared with testosterone esters.
Pathway Targets
Androgen receptor
Scientific explanation
Transcriptional agonism.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
AR-driven anabolism
Target to downstream effect: AR binding → Anabolic gene transcription
Mechanistically Relevant Repurposed & Adjunctive Applications
Historical hereditary angioedema / anabolic labelling
EstablishedMechanistic rationale
Historical labelled uses exist in some markets (including some HAE contexts via fibrinolytic/complement effects). Contemporary availability varies.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| Androgen receptor | Agonism | Anabolic transcription | Established mechanism |
Mechanistic Interaction Considerations
Hepatotoxicity, lipid disturbance, and HPG suppression are expected class risks. Anticoagulant interactions may occur.
In Plain Language
Stanozolol (often misspelled stanazolol) is an oral anabolic steroid: it activates androgen receptors. The same chemistry that lets it survive digestion is harder on the liver.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Androgen receptor
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.